Welcome to our dedicated page for Dogwood Therapeutics SEC filings (Ticker: DWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Dogwood Therapeutics, Inc. (Nasdaq: DWTX) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, giving investors direct insight into how this development-stage biopharmaceutical company reports on its pain and neuropathy programs, capital structure and governance. Dogwood files a range of documents with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, proxy statements on Schedule 14A and registration statements on Form S-3.
Through its Form 8-K filings, Dogwood discloses material events such as securities purchase agreements for registered direct offerings and concurrent private placements, the terms of pre-funded warrants and common stock warrants, and the termination of prior at-the-market offering programs. These filings also describe licensing agreements, including the exclusive, royalty-free global license for SP16 IV, and summarize business combinations and support agreements that affect ownership and voting arrangements.
The company’s definitive proxy statement (DEF 14A) provides detail on stockholder proposals, such as approval of potential issuance of common stock upon conversion of Series A, Series A-1 and Series A-2 non-voting convertible preferred stock under Nasdaq Listing Rule 5635, and approval of the Second Amended and Restated 2020 Equity Incentive Plan. Certificate of designation filings outline the rights and limitations of preferred stock series, including conversion mechanics, voting restrictions and beneficial ownership limits.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that explain the key points of lengthy documents, helping users quickly understand financing terms, equity incentive changes, licensing structures and their implications for DWTX shareholders. Real-time updates from EDGAR ensure that new 8-Ks, proxy materials and registration statements appear promptly, while structured access to filings related to equity issuances, preferred stock conversions and licensing transactions allows focused review of topics most relevant to Dogwood’s clinical and capital plans.
Dogwood Therapeutics, Inc. has called a virtual special meeting on March 11, 2026 to ask stockholders to approve the exercise of a Common Warrant held by an investor and the related issuance of up to 4,386,037 shares of common stock, as required under a January 11, 2026 Securities Purchase Agreement and Nasdaq Listing Rule 5635(d). The company notes that the pre-funded warrant and Common Warrant issued under that agreement together represent about 20.05% of its outstanding shares immediately before the transaction, so full exercise would materially dilute existing holders’ ownership and future earnings per share. A second proposal would allow the meeting to be adjourned to solicit more proxies if there are not enough votes to approve the warrant proposal.
Dogwood Therapeutics, Inc. submitted a current report noting that it has posted a shareholder letter to its website, dated January 20, 2026. The letter provides a corporate update for shareholders and is included as Exhibit 99.1 to the report. The company specifies that this shareholder letter is being furnished for information purposes under securities regulations and is not being treated as filed or incorporated into other securities law filings.
Dogwood Therapeutics, Inc. filed a Form S-3 to register up to 6,433,126 shares of common stock for resale by existing investors, rather than to issue new shares. The shares come from pre-funded warrants with a $0.0001 exercise price and common stock warrants with a $3.28 exercise price that were previously issued to a single institutional investor.
Dogwood will not receive any proceeds from sales of these registered shares, though it could receive cash if any unexercised warrants are exercised. As of January 14, 2026, the company had 32,082,464 shares outstanding, which would rise to 38,515,590 if all related warrants were exercised, and the filing warns that this could substantially dilute existing holders and pressure the share price.
The company is a pre-revenue, development-stage biopharmaceutical business developing Halneuron for cancer and chemotherapy-induced pain and antiviral combinations IMC-1 and IMC-2 for fibromyalgia and Long-COVID. Dogwood estimates Q4 2025 operating expenses of about $3.9 million and cash and equivalents of about $6.5 million as of December 31, 2025, and its auditor’s 2024 report includes a going concern explanatory paragraph.
Dogwood Therapeutics, Inc. completed a combined registered direct offering and concurrent private placement, raising approximately $12.5 million in gross proceeds.
It sold 2,338,948 shares of common stock in the registered deal, plus pre-funded warrants for 2,047,089 shares and common stock warrants for 4,386,037 shares, generally priced around $2.85 per share and accompanying warrant. The common stock warrants become exercisable for five and one-half years after stockholder approval at $3.28 per share, while the pre-funded warrants are immediately exercisable at a nominal price. Dogwood also terminated its prior at-the-market equity program with Northland, under which it had sold only $89,792 of stock out of an authorized $8,558,712.
Dogwood Therapeutics, Inc. is offering 2,338,948 shares of common stock at $2.85 per share in a takedown from its $150 million shelf registration, for gross proceeds of $6,666,002 and estimated net proceeds of approximately $6.0 million. The company plans to use the cash primarily to advance clinical development of its lead non-opioid pain candidate Halneuron® and for working capital and general corporate purposes.
In a concurrent private placement, Dogwood is issuing unregistered pre-funded warrants for up to 2,047,089 shares and unregistered warrants for up to 4,386,037 shares, both outside this prospectus. Management notes cash and cash equivalents of approximately $6.5 million as of December 31, 2025 and recurring operating losses that have led auditors to include a going concern explanatory paragraph, so this equity raise is intended to help support ongoing operations despite significant dilution risk to existing shareholders.
Dogwood Therapeutics, Inc. (DWTX) reported a major insider ownership change as CK Life Sciences–affiliated entities converted non-voting preferred stock into common shares. On November 21, 2025, each share of Series A and Series A-1 Non-Voting Convertible Preferred Stock automatically converted into 10,000 shares of common stock following stockholder approval of the conversion.
Sealbond Limited reported the conversion of preferred stock into 21,610,950 shares of common stock, with 21,822,333 common shares beneficially owned directly afterward. Conjoint Inc., another affiliate, reported the conversion of Series A-1 Preferred Stock into 2,842,638 common shares, held indirectly. CK Life Sciences Int'l., (Holdings) Inc. is listed as a director by deputization and 10% owner through its subsidiaries but disclaims beneficial ownership except for any pecuniary interest.
Dogwood Therapeutics, Inc. reported that stockholders approved several key proposals at a special meeting held on November 21, 2025. The Second Amended and Restated Equity Incentive Plan was approved, increasing the shares of common stock reserved under the prior plan by 2,781,665 shares to a total of 2,972,787 shares. Stockholders also approved the potential issuance of common stock upon conversion of the Company’s Series A, Series A-1, and Series A-2 Non-Voting Convertible Preferred Stock. Following approval of the Series A conversion, the Company’s business combination with Sealbond Limited under the Share Exchange Agreement dated October 7, 2024 is complete. A quorum was present, with 820,239 shares representing 35.76% of voting power as of the record date, and all matters received sufficient votes, including for Nasdaq Listing Rule 5635 purposes.
Dogwood Therapeutics (Nasdaq: DWTX) filed its Q3 2025 10‑Q, reporting a net loss of $15.7 million as R&D climbed, driven by $12.0 million of acquired in‑process R&D tied to a new SP16 license. For the nine months, net loss was $30.5 million, including a $6.1 million loss recognized on a related‑party debt conversion.
Cash was $10,126,710, with net cash used in operating activities of $11,981,464 for the nine months. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond the first quarter of 2026 without additional financing.
During March 2025, the company raised approximately $4.25 million net in a registered direct offering and exchanged $19.9 million of related‑party loans and interest into Series A‑1 Non‑Voting Convertible Preferred Stock. On September 29, 2025, Dogwood licensed SP16 from Serpin, issuing equity valued at $12,030,667. As of November 5, 2025, 2,293,162 common shares were outstanding.
Dogwood Therapeutics (DWTX) furnished an update on its financial performance. On November 6, 2025, the company announced results for the third quarter ended September 30, 2025 via a press release attached as Exhibit 99.1. The information is expressly furnished, not filed under the Exchange Act, which means it is not subject to Section 18 liabilities and is not incorporated by reference into other filings.